Columbia University's Herbert Irving Comprehensive Cancer Center unites the major clinical, population, and basic cancer research efforts of Columbia University community and its affiliated hospitals in its mission to decrease the burden of cancer, through innovation and collaboration. The Cancer Center, initially funded in 1972 and designated comprehensive in 1979, provides the organizational infrastructure to promote interdisciplinary laboratory, clinical and population based cancer research. The Center's primary goal is to promote collaborative interactions leading to new approaches to cancer prevention, diagnosis, and treatment, especially for diverse population in the tri-state region (Northern New Jersey, Southeastern New York and Southwestern Connecticut) served by this Cancer Center. The Cancer Center includes four divisions (Laboratory Research, Clinical Research, Population Science and Core Facilities) comprising 11 programs. Support is requested for 13 shared core facilities that provide state-of-the-art expertise, technology and resources with considerable efficiency and cost savings, senior leadership (the director, 4 associate directors, and 7 additional executive committee members). Funds are also requested for Development, Planning and Evaluation, and Administration to support Center goals. The Cancer Center facilitates the efforts of its 276 members who generate a total of $140.9 million dollars in total research funding and $29.5 million in total NCI funding for 2002. The Cancer Center has experienced considerable growth over the current grant period with a 74% increase in NCI funding. During this funding period the Cancer Center has completed renovation of 6 floors of Irving Pavilion for out patients culminating in the opening of the Children's and Adolescents unit in 2001. The Cancer Center is currently programming a $130 million Irving Cancer Research Building scheduled to open in early 2004 which will contain 7 laboratory floors and 2 floors for animal care at approximately 11,000 net square feet per floor.
| Hernandez, Celine; Huebener, Peter; Pradere, Jean-Philippe et al. (2018) HMGB1 links chronic liver injury to progenitor responses and hepatocarcinogenesis. J Clin Invest 128:2436-2451 |
| Proto, Jonathan D; Doran, Amanda C; Gusarova, Galina et al. (2018) Regulatory T Cells Promote Macrophage Efferocytosis during Inflammation Resolution. Immunity 49:666-677.e6 |
| Kraakman, Michael J; Liu, Qiongming; Postigo-Fernandez, Jorge et al. (2018) PPAR? deacetylation dissociates thiazolidinedione's metabolic benefits from its adverse effects. J Clin Invest 128:2600-2612 |
| Lee, Younghyun; Pujol Canadell, Monica; Shuryak, Igor et al. (2018) Candidate protein markers for radiation biodosimetry in the hematopoietically humanized mouse model. Sci Rep 8:13557 |
| Evans, Lucy P; Newell, Elizabeth A; Mahajan, MaryAnn et al. (2018) Acute vitreoretinal trauma and inflammation after traumatic brain injury in mice. Ann Clin Transl Neurol 5:240-251 |
| Cui, Xuan; Jauregui, Ruben; Park, Karen Sophia et al. (2018) Multimodal characterization of a novel mutation causing vitamin B6-responsive gyrate atrophy. Ophthalmic Genet 39:512-516 |
| Nathan, J; Ruscitto, A; Pylawka, S et al. (2018) Fibrocartilage Stem Cells Engraft and Self-Organize into Vascularized Bone. J Dent Res 97:329-337 |
| Dieck, Chelsea L; Tzoneva, Gannie; Forouhar, Farhad et al. (2018) Structure and Mechanisms of NT5C2 Mutations Driving Thiopurine Resistance in Relapsed Lymphoblastic Leukemia. Cancer Cell 34:136-147.e6 |
| Sengillo, Jesse D; Lee, Winston; Bakhoum, Mathieu F et al. (2018) CHOROIDEREMIA ASSOCIATED WITH A NOVEL SYNONYMOUS MUTATION IN GENE ENCODING REP-1. Retin Cases Brief Rep 12 Suppl 1:S67-S71 |
| Kratchmarov, Radomir; Viragova, Sara; Kim, Min Jung et al. (2018) Metabolic control of cell fate bifurcations in a hematopoietic progenitor population. Immunol Cell Biol 96:863-871 |
Showing the most recent 10 out of 331 publications
